Open access
Sep 2026
Vorinostat for graft-versus-host disease prevention in pediatric and young adult patients with hematologic malignancies.
BACKGROUND This prospective, single-arm, multicenter phase 1/2 trial evaluated vorinostat added to standard graft-versus-host disease (GVHD) prophylaxis in pediatric, adolescent, and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related, HLA-matched unrelated...
Nicolas Parnell, Xiao Cao, J. H. Beumer et al.
· JCI Insight · 0 citations